HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?

What's Driving HUTCHMED (China) Ltd's Surprising 38% Stock Rally?

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years

HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years

What's Driving HUTCHMED (China) Ltd's Surprising 28% Stock Rally?

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China